PO-209 Biological characterisation of specific KRAS mutations: from basic biology to response to treatment
Sign Up to like & getrecommendations! Published in 2018 at "ESMO Open"
DOI: 10.1136/esmoopen-2018-eacr25.244
Abstract: Introduction KRAS is one of the most frequently mutated oncogenes in cancer and KRAS mutations are commonly associated with resistance to therapy and poor prognosis. KRAS is still not directly druggable, therefore current therapeutic strategies… read more here.
Keywords: response; vitro vivo; specific kras; biology ... See more keywords
Abstract 1825: Tumor-targeted knockdown of KRAS mutants with novel Centyrin:siRNA conjugates
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-1825
Abstract: KRAS has been the quintessential undruggable oncogene for many years. Although there have been recently described small molecule inhibitors of KRAS, these molecules only target a specific mutant form, KRAS G12C. The KRAS G12C mutation… read more here.
Keywords: centyrin; centyrin sirna; knockdown kras; kras mutants ... See more keywords
Abstract PHB05: Mechanism-based computational models to study interplay between EGFR inhibitors and KRAS mutants
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.camodels2020-phb05
Abstract: An early genotype-to-phenotype relationship in cancer personalized medicine was that KRAS mutations confer resistance to EGFR inhibitors in colorectal cancer. Confusingly, phase 3 clinical trials found that patients with the KRAS G13D mutation were an… read more here.
Keywords: egfr inhibitors; cancer; computational models; kras g13d ... See more keywords